Analyst consensus rating
Elicio Therapeutics Analyst Rating: Strong Buy
ELTX is rated Strong Buy by 2 analysts with a $16.50 target. As of 2026-08-25.
Direct answer
Elicio Therapeutics's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $16.50.
Forecast evidence checked August 25, 2026.
Get free Elicio Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.98
- Average price target
- $16.50
- High price target
- $23.00
- Low price target
- $10.00
- Low target gap
- +235.6%
- Target upside
- +453.7%
- High target gap
- +671.8%
- Target range width
- 436.2%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- August 25, 2026
- Valid through
- September 1, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Elicio Therapeutics?
Elicio Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $16.50.
How far are Elicio Therapeutics's low and high targets from the recorded price?
The low target implies +235.6%, while the high target implies +671.8%.
How many analysts are included in Elicio Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Elicio Therapeutics's target upside or downside calculated?
The average target of $16.50 is divided by the recorded price of $2.98, then one is subtracted to produce +453.7%. This does not guarantee a future return.
When was Elicio Therapeutics's analyst forecast verified?
The data was verified on 2026-08-25. The dataset is valid through 2026-09-01.